KRAS G12C in myeloma — rare; tissue-agnostic G12Ci (sotorasib/adagrasib) not approved in...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-MM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MM |
| Sources | SRC-CIVIC SRC-NCCN-MM-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | KRAS G12C |
| Disease | DIS-MM |
| ESCAT tier | IV |
| Evidence summary | KRAS G12C in myeloma — rare; tissue-agnostic G12Ci (sotorasib/adagrasib) not approved in heme. Trial-only consideration. |
Notes
ESCAT IV. FLAG: dedicated BIO-KRAS-G12C would improve granularity.
Used By
No reverse references found in the YAML corpus.